Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009
- Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical UseCirculation, 2009
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClinical Chemistry, 2009
- Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in WomenCirculation, 2009
- Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practiceJournal of Clinical Lipidology, 2008
- Utility of Non–High-Density Lipoprotein Cholesterol Versus Other Lipoprotein Measures in Detecting Subclinical Atherosclerosis in Young Adults (The Bogalusa Heart Study)The American Journal of Cardiology, 2007
- Non–High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic TargetThe American Journal of Cardiology, 2005
- Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein BThe American Journal of Cardiology, 2005
- Population frequency distribution of non–high-density lipoprotein cholesterol (third national health and nutrition examination survey [NHANES iii], 1988–1994)The American Journal of Cardiology, 2000